Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
641-660 of 1,738 trials

BRAF-V600E Mutant Metastatic Colorectal Cancer: BRAVE Trial

We are studying a combination of encorafenib, cetuximab, and bevacizumab for patients with BRAF-V600E mutated metastatic colorectal cancer who have not responded to previous treatments. The trial aims to evaluate the safety and effectiveness of this treatment approach.

Metastatic Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Spinal Cord Injury: TZ-161 Treatment Study

We are testing a new treatment for adults with early acute spinal cord injury to see if it is safe and effective compared to standard care. The study will also evaluate its effects on pain and recovery time.

Early Acute Spinal Cord Injury1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesNeurology

Acute Myeloid Leukemia: CD19 CAR-T Cell Therapy

We are studying the safety of a new CAR-T cell treatment for patients with refractory acute myeloid leukemia. This trial aims to see how well the treatment works and how long the CAR-T cells last in the body.

Recurrent Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Non-Small Cell Lung Cancer: New Treatment Combinations with Pembrolizumab

We are studying new investigational treatments combined with pembrolizumab and chemotherapy for patients with newly diagnosed resectable non-small cell lung cancer. The goal is to see how well these combinations work and their safety before surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesOncology

Asthma Treatment: Atuliflapon Study

We are investigating whether Atuliflapon can improve symptoms in adults with moderate to severe uncontrolled asthma. This study compares its effects to a placebo to ensure safety and efficacy.

Moderate-to-Severe Uncontrolled Asthma3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Indolent Non-Hodgkin's Lymphoma: EO2463 Cancer Vaccine

We are investigating a new cancer vaccine, EO2463, for patients with indolent Non-Hodgkin's Lymphoma. The trial aims to assess its safety and effectiveness alone and with other treatments.

Indolent Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyPulmonology

Melanoma Treatment: Nivolumab with Isolated Limb Perfusion

We are studying whether combining nivolumab with isolated limb perfusion helps patients with in-transit melanoma metastases achieve better treatment responses. This trial will also look at safety and quality of life.

In-transit Metastasis of Malignant Melanoma1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteDermatologyOncology

ColiFin® Therapy for Adults with Bronchiectasis and Pseudomonas Infection

We are studying whether inhaled ColiFin® can improve health in adults with bronchiectasis who have a new asymptomatic Pseudomonas aeruginosa infection. The trial compares this treatment to standard care to see which is more effective.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Lobular Breast Cancer: Capivasertib and Fulvestrant Study

We are studying a new treatment combination for patients with high-risk lobular breast cancer to see if it improves cancer control and safety compared to standard therapy.

Invasive Lobular Breast Carcinoma≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Late-Onset Pompe Disease: SPK-3006 Infusion Study

We are testing a new intravenous treatment for adults with late-onset Pompe disease to evaluate its safety and potential benefits. This study will help us understand how well the treatment works and how it is tolerated.

Pompe Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterologyHematologyNeurology

Gastroesophageal Adenocarcinoma: MK-2870 with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for patients with advanced gastroesophageal adenocarcinoma. The goal is to evaluate its safety and how well it may help manage the disease.

Gastroesophageal CancerSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesOncology

Lupus Nephritis: LNP023 Treatment Study

We are studying the safety and effectiveness of LNP023 in adults with active lupus nephritis. The goal is to see if it helps improve kidney function compared to standard treatments.

Lupus Nephritis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNephrologyRheumatology

Lung Transplant Rejection: Stem Cell Treatment Study

We are studying the safety of a new stem cell treatment for patients experiencing chronic rejection after a lung transplant. This trial aims to see if it can help slow down the progression of their condition.

Bronchiolitis Obliterans Syndrome (BOS)6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicinePulmonology

Multiple Myeloma: CC-92480 Combination Study

We are exploring a new treatment combination for people with relapsed or refractory multiple myeloma. The study aims to assess safety and how well it works compared to standard treatments.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Dilated Cardiomyopathy: Risedronate Treatment

We are studying whether Risedronate can improve heart function in patients with dilated cardiomyopathy caused by a Troponin T gene mutation. We also want to assess its safety and impact on physical performance.

Dilated Cardiomyopathy1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Raynaud’s Phenomenon: Sodium Thiosulfate Study

We are exploring how different doses of an intravenous medication, sodium thiosulfate, may help improve blood flow in people with Raynaud’s phenomenon. The study will also look at the safety and how the body reacts to the treatment.

Raynaud's PhenomenonEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Schizophrenia Spectrum Disorders: Oxytocin Treatment Study

We are investigating whether intranasal oxytocin can enhance social skills and functioning in individuals with schizophrenia spectrum disorders. This study compares oxytocin to a placebo alongside standard psychosocial treatment.

Schizophrenia6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry